BioVie completes enrollment in Long COVID trial as need for treatments grows

BioVie CEO Cuong Do joined Steve Darling from Proactive to announce the successful completion of patient enrollment for the company’s ADDRESS-LC Phase 2 clinical study evaluating its drug candidate bezisterim for the treatment of neurological symptoms associated with Long COVID. The study marks an important milestone for the company and is fully funded through a grant from the U.S. Department of Defense, helping advance the program without additional financing pressures tied directly to the trial.

Do highlighted the growing healthcare challenge posed by Long COVID, which continues to affect millions of individuals long after their initial infection. According to estimates, approximately 15 million adults in the United States reported experiencing Long COVID between 2022 and 2023, with roughly 3.8 million indicating that symptoms significantly interfered with their daily activities and quality of life. The persistence of symptoms has created an increasing need for effective treatment options and greater clinical understanding of the condition.

He explained that nearly half of individuals experiencing Long COVID develop symptoms that can persist either continuously or intermittently over extended periods. Among the most common and debilitating complications are neurological symptoms, which often include fatigue, cognitive impairment commonly referred to as “brain fog,” persistent cognitive dysfunction, post-exertional malaise, and sleep disturbances. These symptoms can create significant physical and emotional challenges for patients and have emerged as one of the major areas of focus in Long COVID research.

BioVie noted that advancing scientific understanding continues to strengthen the rationale for bezisterim’s proposed mechanism of action. The company believes that growing evidence increasingly points to chronic inflammation and ongoing immune system activity as key contributors to many Long COVID symptoms, particularly those affecting neurological and neuropsychiatric function. Bezisterim is designed to target inflammatory pathways that may be driving these persistent symptoms.

Despite growing awareness of Long COVID and increasing research efforts, treatment options remain limited. BioVie emphasized that there are currently no FDA-approved therapies specifically designed to treat Long COVID, leaving a significant unmet medical need and potentially creating a substantial opportunity for therapies capable of addressing the condition effectively.
proactiveinvestors #biovieince #nasdaq #bivi #LongCOVID #ClinicalTrials #Biotech #DrugDevelopment #MedicalResearch #Neurology #HealthcareInnovation #Phase2Trial #Biopharma

Видео BioVie completes enrollment in Long COVID trial as need for treatments grows канала Proactive Investors